Please note that login will be disabled for maintenance during the period: 13:00 - 14:00 GMT

Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Conferences

ecancer travels so that you don't have to. Explore the latest conference coverage in global oncology and find out where we are going next.

ASCO GI 2022

20 - 22 Jan 2022

Moscone West, San Francisco, United States of America

ASCO GI 2022: Ripretinib demonstrates comparable efficacy and fewer side effects compared to sunitinib in patients with GIST previously treated with imatinib

ASCO GI 2022: Ripretinib demonstrates comparable efficacy and fewer side effects compared to sunitinib in patients...

ASCO GI 2022: Durvalumab plus tremelimumab significantly improves survival for patients with advanced liver cancer compared to sorafenib

ASCO GI 2022: Durvalumab plus tremelimumab significantly improves survival for patients with advanced liver cancer...

ASCO GI 2022: Durvalumab significantly improves survival for patients with biliary tract cancer compared to chemotherapy alone

ASCO GI 2022: Durvalumab significantly improves survival for patients with biliary tract cancer compared to...

ASCO GI 2022: Pembrolizumab significantly improved OS versus placebo in certain patients with advanced HCC previously treated with sorafenib

ASCO GI 2022: Pembrolizumab significantly improved OS versus placebo in certain patients with advanced HCC...

More from ecancer